Atorvastatin (Lipitor®): A review of its pharmacological and clinical profile

Folia Pharmacologica Japonica

Volumn 117, Issue 1, 2001, Pages 65-76

  Funatsu, T ^a   Kakuta, H ^a   Tanaka, H ^a   Arai, Y ^a   Suzuki, K ^a   Miyata, K ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Atherosclerosis; Atorvastatin; HMG CoA reductase inhibitors; LDL receptors; VLDL secretion

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; PYRROLE DERIVATIVE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; JAPAN; PROTEIN SECRETION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ARTERIOSCLEROSIS; LIVER; METABOLISM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; CLINICAL TRIALS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LIPOPROTEINS, VLDL; LIVER; PYRROLES; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 0035163381     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.117.65     Document Type: Review

References (50)

1. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men
2. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men
3. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study
4. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
8. Assembly of very low density lipoprotein in the hepatocyte. Differential transport of apoproteins through the secretory pathway
9. Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster
10. Molecular physiology of reverse cholesterol transport
11. Lipoprotein metabolism and its relationship to atherosclerosis
12. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study
13. Coronary plaque disruption
14. Current concepts in cardiovascular pathology: The role of LDL cholesterol in plaque rupture and stabilization
15. Pharmacologic profile of YM548, a novel HMG-CoA reductase inhibitor, in HepG2 cells
16. Inhibition of sterol synthesis and lipid reduction by YM548, a novel HMG-CoA reductase inhibitor
17. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin
18. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys
19. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug
20. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
21. A receptor-mediated pathway for cholesterol homeostasis
22. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs
23. The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits
24. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men
25. Role of cholesterol in regulating apolipoprotein B secretion by the liver
26. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion
27. The assembly and secretion of ApoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins
28. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells
29. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs
30. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits
31. The effect of atorvastatin, a new HMG-CoA reductase inhibitor, and LDL-apheresis on homozygous familial hypercholesterolemia
32. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
33. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
34. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels